- Home
- IRS vs NTLA Comparison
IRS vs NTLA Comparison
Compare IRS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- NTLA
- Stock Information
- Founded
- IRS 1943
- NTLA 2014
- Country
- IRS Argentina
- NTLA United States
- Employees
- IRS N/A
- NTLA 598
- Industry
- IRS Homebuilding
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IRS Real Estate
- NTLA Health Care
- Exchange
- IRS Nasdaq
- NTLA Nasdaq
- Market Cap
- IRS 873.6M
- NTLA 710.1M
- IPO Year
- IRS 1994
- NTLA 2016
- Fundamental
- Price
- IRS $14.62
- NTLA $8.21
- Analyst Decision
- IRS Strong Buy
- NTLA Buy
- Analyst Count
- IRS 1
- NTLA 19
- Target Price
- IRS $12.62
- NTLA $38.47
- AVG Volume (30 Days)
- IRS 148.1K
- NTLA 3.8M
- Earning Date
- IRS 05-06-2025
- NTLA 05-08-2025
- Dividend Yield
- IRS 11.32%
- NTLA N/A
- EPS Growth
- IRS N/A
- NTLA N/A
- EPS
- IRS N/A
- NTLA N/A
- Revenue
- IRS $325,094,048.00
- NTLA $57,877,000.00
- Revenue This Year
- IRS N/A
- NTLA N/A
- Revenue Next Year
- IRS N/A
- NTLA N/A
- P/E Ratio
- IRS N/A
- NTLA N/A
- Revenue Growth
- IRS N/A
- NTLA 59.55
- 52 Week Low
- IRS $8.21
- NTLA $5.90
- 52 Week High
- IRS $17.67
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- IRS 55.31
- NTLA 51.69
- Support Level
- IRS $13.63
- NTLA $6.73
- Resistance Level
- IRS $14.65
- NTLA $7.76
- Average True Range (ATR)
- IRS 0.99
- NTLA 0.71
- MACD
- IRS 0.18
- NTLA 0.24
- Stochastic Oscillator
- IRS 81.38
- NTLA 73.00
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.